Share on StockTwits

Edwards Lifesciences Corp (NYSE:EW) VP Larry L. Wood unloaded 63,752 shares of the company’s stock on the open market in a transaction dated Monday, August 18th. The shares were sold at an average price of $97.85, for a total value of $6,238,133.20. Following the sale, the vice president now directly owns 39,757 shares in the company, valued at approximately $3,890,222. The sale was disclosed in a document filed with the SEC, which is available at this link.

Edwards Lifesciences Corp (NYSE:EW) traded up 0.08% on Tuesday, hitting $97.97. 580,853 shares of the company’s stock traded hands. Edwards Lifesciences Corp has a one year low of $60.62 and a one year high of $98.27. The stock has a 50-day moving average of $89.95 and a 200-day moving average of $80.21. The company has a market cap of $10.388 billion and a price-to-earnings ratio of 14.13. Edwards Lifesciences Corp also was the target of a significant drop in short interest in the month of July. As of July 31st, there was short interest totalling 2,915,578 shares, a drop of 45.6% from the July 15th total of 5,356,970 shares. Approximately 2.8% of the shares of the company are sold short. Based on an average trading volume of 1,687,462 shares, the short-interest ratio is currently 1.7 days.

Edwards Lifesciences Corp (NYSE:EW) last posted its quarterly earnings results on Tuesday, July 29th. The company reported $0.88 EPS for the quarter, beating the Thomson Reuters consensus estimate of $0.77 by $0.11. The company had revenue of $547.00 million for the quarter, compared to the consensus estimate of $545.10 million. During the same quarter in the prior year, the company posted $0.82 earnings per share. The company’s quarterly revenue was up 11.2% on a year-over-year basis. On average, analysts predict that Edwards Lifesciences Corp will post $3.29 earnings per share for the current fiscal year.

A number of research firms have recently commented on EW. Analysts at Stifel Nicolaus raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Separately, analysts at JPMorgan Chase & Co. raised their price target on shares of Edwards Lifesciences Corp from $78.00 to $90.00 in a research note on Thursday, July 31st. Finally, analysts at CRT Capital raised their price target on shares of Edwards Lifesciences Corp from $90.00 to $100.00 in a research note on Thursday, July 31st. Five research analysts have rated the stock with a hold rating and eight have issued a buy rating to the stock. The stock has a consensus rating of “Buy” and an average price target of $90.06.

Edwards Lifesciences Corporation (NYSE:EW) is focused on technologies that treat structural heart disease and critically ill patients.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.